BR0012489A - Composto, composição farmacêutica, uso de um composto, e, kit para a contracepção masculina - Google Patents
Composto, composição farmacêutica, uso de um composto, e, kit para a contracepção masculinaInfo
- Publication number
- BR0012489A BR0012489A BR0012489-3A BR0012489A BR0012489A BR 0012489 A BR0012489 A BR 0012489A BR 0012489 A BR0012489 A BR 0012489A BR 0012489 A BR0012489 A BR 0012489A
- Authority
- BR
- Brazil
- Prior art keywords
- compound
- alkyl
- kit
- pharmaceutical composition
- hydrogen
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title abstract 5
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 2
- 125000000217 alkyl group Chemical group 0.000 abstract 5
- 229910052739 hydrogen Inorganic materials 0.000 abstract 5
- 239000001257 hydrogen Substances 0.000 abstract 3
- 125000002252 acyl group Chemical group 0.000 abstract 2
- 229910052736 halogen Inorganic materials 0.000 abstract 2
- 150000002367 halogens Chemical group 0.000 abstract 2
- 150000002431 hydrogen Chemical class 0.000 abstract 2
- VGGSQFUCUMXWEO-UHFFFAOYSA-N Ethene Chemical compound C=C VGGSQFUCUMXWEO-UHFFFAOYSA-N 0.000 abstract 1
- 239000005977 Ethylene Substances 0.000 abstract 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 abstract 1
- 125000003342 alkenyl group Chemical group 0.000 abstract 1
- 125000000304 alkynyl group Chemical group 0.000 abstract 1
- 239000003098 androgen Substances 0.000 abstract 1
- 229940030486 androgens Drugs 0.000 abstract 1
- 125000000298 cyclopropenyl group Chemical group [H]C1=C([H])C1([H])* 0.000 abstract 1
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 abstract 1
- 229960004719 nandrolone Drugs 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J1/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, not substituted in position 17 beta by a carbon atom, e.g. estrane, androstane
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J1/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, not substituted in position 17 beta by a carbon atom, e.g. estrane, androstane
- C07J1/0051—Estrane derivatives
- C07J1/0066—Estrane derivatives substituted in position 17 beta not substituted in position 17 alfa
- C07J1/007—Estrane derivatives substituted in position 17 beta not substituted in position 17 alfa the substituent being an OH group free esterified or etherified
- C07J1/0074—Esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/16—Masculine contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/26—Androgens
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J1/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, not substituted in position 17 beta by a carbon atom, e.g. estrane, androstane
- C07J1/0051—Estrane derivatives
- C07J1/0066—Estrane derivatives substituted in position 17 beta not substituted in position 17 alfa
- C07J1/007—Estrane derivatives substituted in position 17 beta not substituted in position 17 alfa the substituent being an OH group free esterified or etherified
Landscapes
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Endocrinology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Public Health (AREA)
- Diabetes (AREA)
- Reproductive Health (AREA)
- Steroid Compounds (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Abstract
"COMPOSTO, COMPOSIçãO FARMACêUTICA, USO DE UM COMPOSTO, E, KIT PARA A CONTRACEPçãO MASCULINA". Andrógenos oralmente ativos, novos, são derivados de <30>^ 14^-nandrolona 7<244> substituídos. Os compostos satisfazem à fórmula (I) em que R~ 1~ é O, (H, H), (H,OR), NOR, com R sendo hidrogênio, alquila (C~ 1-6~) ou acila (C~ 1-6~); R~ 2~ é selecionado a partir do grupo, que consiste em alquila (C~ 2-4~), alquenila (C~ 2-4~), ou alquinila (C~ 2-4~), cada qual opcionalmente substituido por halogênio; ou R~ 2~ é ciclopropila, ou ciclopropenila, cada qual opcionalmente substituído por alquila (C~ 1-2~), ou halogênio; R~ 3~ é hidrogênio, alquila (C~ 1-2~), ou etenila; R~ 4~ é alquila (C~ 1-2~); R~ 5~ é hidrogênio, ou acila (C~ 1-15~); e as linhas pontilhadas indicam ligações opcionais.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP99202348 | 1999-07-16 | ||
| PCT/EP2000/006544 WO2001005806A1 (en) | 1999-07-16 | 2000-07-10 | Orally active androgens |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR0012489A true BR0012489A (pt) | 2002-04-02 |
Family
ID=8240463
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR0012489-3A BR0012489A (pt) | 1999-07-16 | 2000-07-10 | Composto, composição farmacêutica, uso de um composto, e, kit para a contracepção masculina |
Country Status (28)
| Country | Link |
|---|---|
| US (3) | US6313108B1 (pt) |
| EP (1) | EP1203011B1 (pt) |
| JP (1) | JP2003505394A (pt) |
| KR (1) | KR20020092890A (pt) |
| CN (1) | CN1360589A (pt) |
| AR (1) | AR024746A1 (pt) |
| AT (1) | ATE257159T1 (pt) |
| AU (1) | AU770412B2 (pt) |
| BR (1) | BR0012489A (pt) |
| CA (1) | CA2379223A1 (pt) |
| CO (1) | CO5200765A1 (pt) |
| CZ (1) | CZ2002192A3 (pt) |
| DE (1) | DE60007530T2 (pt) |
| ES (1) | ES2213596T3 (pt) |
| HK (1) | HK1043797A1 (pt) |
| HU (1) | HUP0201952A3 (pt) |
| IL (1) | IL147332A0 (pt) |
| MX (1) | MXPA02000601A (pt) |
| NO (1) | NO20020222L (pt) |
| NZ (1) | NZ516525A (pt) |
| PE (1) | PE20010330A1 (pt) |
| PL (1) | PL353007A1 (pt) |
| RU (1) | RU2002103883A (pt) |
| SK (1) | SK712002A3 (pt) |
| TR (1) | TR200200076T2 (pt) |
| TW (1) | TW548277B (pt) |
| WO (1) | WO2001005806A1 (pt) |
| ZA (1) | ZA200200106B (pt) |
Families Citing this family (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6756366B1 (en) * | 1999-04-06 | 2004-06-29 | Akzo Nobel N.V. | Orally active androgens |
| US20030069215A1 (en) * | 2001-03-30 | 2003-04-10 | The Government Of The United States Of America, | Methods of making and using 7a,11b-dimethyl-17b-hydroxy-4-estren-3-one 17b-trans-4-n-butylcyclohexane carboxylate and 7a,11b-dimethyl-17b-hydroxyestr-4-en-3-one 17-undecanoate |
| CA2402524C (en) * | 2000-03-31 | 2009-11-17 | Richard P. Blye | Methods of making and using 7.alpha.,11.beta.-dimethyl-17.beta.-hydroxy-4-estren-3-one 17.beta.-trans-4-n-butylcyclohexane carboxylate and 7.alpha.,11.beta.-dimethyl-17.beta.-hydroxyestr-4-en-3-one 17-undecanoate |
| MXPA03000845A (es) * | 2000-07-28 | 2004-04-05 | Akzo Nobel Nv | Estrogenos substituidos por 16alfa-metilo o etilo. |
| JP2005510541A (ja) * | 2001-03-30 | 2005-04-21 | アメリカ合衆国 | ７α，１１β−ジメチル−１７β−ヒドロキシエストラ−４，１４−ジエン−３−オン及びその１７エステルの製造方法及びそれらを含有する医薬製剤 |
| TWI322813B (en) * | 2002-01-21 | 2010-04-01 | Organon Nv | Process for the preparation of 7alpha-methylsteroids |
| GB0304927D0 (en) * | 2003-03-04 | 2003-04-09 | Resolution Chemicals Ltd | Process for the production of tibolone |
| PE20050677A1 (es) | 2003-12-22 | 2005-10-04 | Akzo Nobel Nv | Esteroides con perfil androgenico y progestagenico mixto |
| UA89964C2 (ru) | 2004-09-08 | 2010-03-25 | Н.В. Органон | 15β-ЗАМЕЩЕННЫЕ СТЕРОИДЫ, КОТОРЫЕ ИМЕЮТ СЕЛЕКТИВНУЮ ЭСТРОГЕННУЮ АКТИВНОСТЬ |
| EP2350111A1 (en) * | 2008-10-15 | 2011-08-03 | Synthon B.V. | Processes and intermediates for the production of fulvestrant |
| CN107266514A (zh) | 2011-06-01 | 2017-10-20 | 埃斯特拉私人有限责任公司 | 用于产生雌四醇中间体的方法 |
| BR112013030833B1 (pt) * | 2011-06-01 | 2019-09-03 | Estetra S A | processo para a preparação de um composto de fórmula (i) e processo para a preparação de estetrol |
| EP2383279A1 (en) | 2011-07-19 | 2011-11-02 | Pantarhei Bioscience B.V. | Process for the preparation of estetrol |
| PT2764008T (pt) * | 2011-10-07 | 2016-11-10 | Estetra Sprl | Processo para a produção de estetrol |
| WO2015181116A1 (en) | 2014-05-26 | 2015-12-03 | Crystal Pharma, S.A.U. | Process and intermediades for the preparation of 7-alkylated steroids |
| WO2016203009A1 (en) | 2015-06-18 | 2016-12-22 | Mithra Pharmaceuticals S.A. | Orodispersible tablet containing estetrol |
| US20160367567A1 (en) | 2015-06-18 | 2016-12-22 | Mithra Pharmaceuticals S.A. | Orodispersible dosage unit containing an estetrol component |
| EP3310346B1 (en) | 2015-06-18 | 2021-03-24 | Estetra SPRL | Orodispersible tablet containing estetrol |
| PL3310333T3 (pl) | 2015-06-18 | 2020-07-13 | Estetra Sprl | Ulegająca rozpadowi w jamie ustnej jednostka dawkowana zawierająca składnik estetrolowy |
| CA3178291A1 (en) | 2016-08-05 | 2018-04-12 | Estetra Srl | Method for the management of dysmenorrhea and menstrual pain |
| ES2906117T3 (es) * | 2017-02-23 | 2022-04-13 | Siemens Healthcare Diagnostics Inc | Conjugados de androstenodiona quimioluminiscente |
| JOP20200260A1 (ar) | 2018-04-19 | 2019-10-19 | Estetra Sprl | مركبات واستخداماتها للتخفيف من الأعراض المصاحبة لانقطاع الطمث |
| TWI801561B (zh) | 2018-04-19 | 2023-05-11 | 比利時商依思特拉私人有限責任公司 | 化合物及其用於緩解絕經相關症狀的用途 |
| TWI893101B (zh) | 2020-04-16 | 2025-08-11 | 比利時商埃斯特拉有限責任公司 | 具有降低之副作用之避孕組成物 |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ZA712312B (en) * | 1970-04-28 | 1972-01-26 | Ochsner Med Found Alton | 4,14-estradiene compounds |
-
2000
- 2000-06-27 TW TW089112646A patent/TW548277B/zh not_active IP Right Cessation
- 2000-07-10 IL IL14733200A patent/IL147332A0/xx unknown
- 2000-07-10 NZ NZ516525A patent/NZ516525A/xx unknown
- 2000-07-10 AT AT00953032T patent/ATE257159T1/de not_active IP Right Cessation
- 2000-07-10 AU AU65629/00A patent/AU770412B2/en not_active Ceased
- 2000-07-10 CN CN00810310A patent/CN1360589A/zh active Pending
- 2000-07-10 MX MXPA02000601A patent/MXPA02000601A/es not_active Application Discontinuation
- 2000-07-10 SK SK71-2002A patent/SK712002A3/sk unknown
- 2000-07-10 DE DE60007530T patent/DE60007530T2/de not_active Expired - Fee Related
- 2000-07-10 PL PL00353007A patent/PL353007A1/xx not_active IP Right Cessation
- 2000-07-10 RU RU2002103883/04A patent/RU2002103883A/ru unknown
- 2000-07-10 EP EP00953032A patent/EP1203011B1/en not_active Expired - Lifetime
- 2000-07-10 BR BR0012489-3A patent/BR0012489A/pt not_active IP Right Cessation
- 2000-07-10 CZ CZ2002192A patent/CZ2002192A3/cs unknown
- 2000-07-10 JP JP2001511464A patent/JP2003505394A/ja not_active Withdrawn
- 2000-07-10 HU HU0201952A patent/HUP0201952A3/hu unknown
- 2000-07-10 CA CA002379223A patent/CA2379223A1/en not_active Abandoned
- 2000-07-10 WO PCT/EP2000/006544 patent/WO2001005806A1/en not_active Ceased
- 2000-07-10 ES ES00953032T patent/ES2213596T3/es not_active Expired - Lifetime
- 2000-07-10 TR TR2002/00076T patent/TR200200076T2/xx unknown
- 2000-07-10 HK HK02105466.2A patent/HK1043797A1/zh unknown
- 2000-07-10 KR KR1020027000566A patent/KR20020092890A/ko not_active Withdrawn
- 2000-07-11 US US09/613,350 patent/US6313108B1/en not_active Expired - Fee Related
- 2000-07-13 CO CO00052876A patent/CO5200765A1/es not_active Application Discontinuation
- 2000-07-14 AR ARP000103625A patent/AR024746A1/es not_active Application Discontinuation
- 2000-07-14 PE PE2000000702A patent/PE20010330A1/es not_active Application Discontinuation
-
2001
- 2001-07-31 US US09/918,626 patent/US6541465B2/en not_active Expired - Fee Related
-
2002
- 2002-01-04 ZA ZA200200106A patent/ZA200200106B/xx unknown
- 2002-01-15 NO NO20020222A patent/NO20020222L/no not_active Application Discontinuation
- 2002-10-24 US US10/280,038 patent/US6780854B2/en not_active Expired - Fee Related
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR0012489A (pt) | Composto, composição farmacêutica, uso de um composto, e, kit para a contracepção masculina | |
| MX222092B (es) | Derivados de n2-fenil-amidina. | |
| BR0012434A (pt) | Composto, processo para a preparação do mesmo, uso de um composto, composição farmacêutica. | |
| BR0207216A (pt) | Derivados de tieno 2,3-d-pirimidindiona como inibidores de metaloproteinase matriz | |
| DK1177176T3 (da) | Triarylsyrederivater som PPAR-receptorligander | |
| BR9813989A (pt) | Composto, processo para prepará-lo, uso do mesmo, composição farmacêutica, e, processo para o tratamento de um paciente sofrendo de uma condição | |
| BR0309534A (pt) | Composto, composição farmacêutica, e, uso de um composto | |
| BRPI0408284B8 (pt) | compostos derivados de ftalazinona, seu uso e composição farmacêutica compreendendo os mesmos | |
| DK1392714T3 (da) | Steroider som agonister for FXR | |
| BR0214023A (pt) | Derivados de 1,2,4-tiadiazólio como moduladores de receptor de melanocortina | |
| BR0014060A (pt) | Derivado de quinolil propil piperidina, processo para preparação do mesmo, e, composição farmacêutica | |
| BR9803179A (pt) | Antagonistas receptores de ccr-3. | |
| BR0115580A (pt) | Derivados de 3-aroilindol e a utilizaçao dos mesmos como agonistas dos receptores cb2 | |
| AR005706A1 (es) | Inhibidores egfr de 4-aminoquinzolina, procedimiento para su obtencion, composicion farmaceutica que los contiene, uso de los mismos para lapreparacion de un medicamento util como agente antineoplasico | |
| BR9915403A (pt) | Antagonistas receptores iii de 4-aroil-piperidin-ccr-3 | |
| PE20020473A1 (es) | USO COMBINADO DE INHIBIDORES DE ACETILCOLINESTERASA Y AGONISTAS INVERSOS DE GABAa PARA EL TRATAMIENTO DE TRASTORNOS COGNITIVOS | |
| HRP20090162T1 (en) | Quinolinone-carboxamide compounds as 5-ht4 receptor agonists | |
| BR9915735A (pt) | Antagonistas receptores de ccr-3 de piperidina | |
| BR0212353A (pt) | Composto, composição farmacêutica, e, uso de um composto | |
| DK1204658T3 (da) | Benzofurylpiperazin-serotoninagonister | |
| BR0211425A (pt) | Método para a preparação de compostos, e, uso de uma composição | |
| BRPI0510397A (pt) | compostos, composições farmacêuticas contendo os mesmos, e métodos de uso dos mesmos | |
| BR0013769A (pt) | Esteróides estrogênicos não aromáticos, composição farmacêutica, e, uso de um composto esteróide | |
| BR0308890A (pt) | Composto | |
| MX9101948A (es) | Composicion farmaceutica que contiene derivados de tiazoloisoindolinona |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: REFERENTE A 5A, 6A E 7A ANUIDADES. |
|
| B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 1927 DE 11/12/2007. |